Abstract
In many types of solid tumours, the aberrant expression of the cell adhesion molecule N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the acquisition of an aggressive tumour phenotype. This transition endows tumour cells with the capacity to escape from the confines of the primary tumour and metastasise to secondary sites. In this review, we will discuss how N-cadherin actively promotes the metastatic behaviour of tumour cells, including its involvement in critical signalling pathways which mediate these events. In addition, we will explore the emerging role of N-cadherin in haematological malignancies, including bone marrow homing and microenvironmental protection to anti-cancer agents. Finally, we will discuss the evidence that N-cadherin may be a viable therapeutic target to inhibit cancer metastasis and increase tumour cell sensitivity to existing anti-cancer therapies.
| Language | English |
|---|---|
| Article number | 939 |
| Journal | BMC Cancer |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Oct 2018 |
Keywords
- Cancer
- Haematological malignancies
- Metastasis
- N-cadherin
- Therapeutic target
ASJC Scopus subject areas
- Oncology
- Genetics
- Cancer Research
Cite this
}
N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology. / Mrozik, Krzysztof Marek; Blaschuk, Orest William; Cheong, Chee Man; Zannettino, Andrew; Vandyke, Kate.
In: BMC Cancer, Vol. 18, No. 1, 939, 01.10.2018.Research output: Contribution to journal › Review article
TY - JOUR
T1 - N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology
AU - Mrozik, Krzysztof Marek
AU - Blaschuk, Orest William
AU - Cheong, Chee Man
AU - Zannettino, Andrew
AU - Vandyke, Kate
PY - 2018/10/1
Y1 - 2018/10/1
N2 - In many types of solid tumours, the aberrant expression of the cell adhesion molecule N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the acquisition of an aggressive tumour phenotype. This transition endows tumour cells with the capacity to escape from the confines of the primary tumour and metastasise to secondary sites. In this review, we will discuss how N-cadherin actively promotes the metastatic behaviour of tumour cells, including its involvement in critical signalling pathways which mediate these events. In addition, we will explore the emerging role of N-cadherin in haematological malignancies, including bone marrow homing and microenvironmental protection to anti-cancer agents. Finally, we will discuss the evidence that N-cadherin may be a viable therapeutic target to inhibit cancer metastasis and increase tumour cell sensitivity to existing anti-cancer therapies.
AB - In many types of solid tumours, the aberrant expression of the cell adhesion molecule N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the acquisition of an aggressive tumour phenotype. This transition endows tumour cells with the capacity to escape from the confines of the primary tumour and metastasise to secondary sites. In this review, we will discuss how N-cadherin actively promotes the metastatic behaviour of tumour cells, including its involvement in critical signalling pathways which mediate these events. In addition, we will explore the emerging role of N-cadherin in haematological malignancies, including bone marrow homing and microenvironmental protection to anti-cancer agents. Finally, we will discuss the evidence that N-cadherin may be a viable therapeutic target to inhibit cancer metastasis and increase tumour cell sensitivity to existing anti-cancer therapies.
KW - Cancer
KW - Haematological malignancies
KW - Metastasis
KW - N-cadherin
KW - Therapeutic target
UR - http://www.scopus.com/inward/record.url?scp=85054215251&partnerID=8YFLogxK
U2 - 10.1186/s12885-018-4845-0
DO - 10.1186/s12885-018-4845-0
M3 - Review article
VL - 18
JO - BMC cancer
T2 - BMC cancer
JF - BMC cancer
SN - 1471-2407
IS - 1
M1 - 939
ER -